Sector News

Global green light for Merck KGaA/Sigma merger

August 12, 2015
Life sciences
Merck KGaA has been granted unconditional permission by regulatory authorities in Brazil to purchase US life sciences group Sigma-Aldrich, which means the firm has now secured approvals from all relevant jurisdictions for its planned acquisition.
 
The German drugmaker said it expects to complete the transaction sometime in the third quarter of this year, creating a business with combined sales of 4.7 billion euros (based on 2013 financials).
 
The timeframe for deal completion has been slightly extended to allow commitments made to the European Commission under its conditional approval of the deal – i.e. the sale of parts of Sigma-Aldrich’s solvents and inorganics business in the region – to be met.
 
The companies first unveiled their $17 billion merger in September last year, in a move to establish “one of the leading players in the $130 billion global life science industry,” with the ability to offer customers “a highly attractive set of established brands and an efficient supply chain that can support the delivery of more than 300,000 products”, according to Merck.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.